Ross J. Maxwell

TL;DR: Experts assembled to review, debate and summarize the challenges of IB validation and qualification produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical validation, biological/clinical validation and assessment of cost-effectiveness.

TL;DR: CA4P acutely reduces Ktrans in human as well as rat tumors at well-tolerated doses, with no significant changes in kidney or muscle, providing proof of principle that this drug has tumor antivascular activity in rats and humans.

TL;DR: These technologies are reviewed, emphasizing magnetic resonance spectroscopy and positron emission tomography, which provide detailed functional and metabolic information and are likely to be more cost-effective than those that measure specific molecular targets.

TL;DR: It is demonstrated that this metabolic pathway is a major contributor to aerobic respiration in primary-cultured cells isolated from human glioma and grown under serum-free conditions and inhibiting fatty acid oxidation reduces proliferative activity in these primary- Cultured cells and prolongs survival in a syngeneic mouse model of malignant gliomas.

TL;DR: Ktrans values for Gd‐DTPA uptake into tumours could be a useful non‐invasive indicator of blood flow changes induced by anti‐vascular agents such as combretastatin.